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ABSTRACT
Mirtrons are introns that form pre-miRNA hairpins after splicing to produce RNA interference (RNAi) effectors distinct from
Drosha-dependent intronic miRNAs. Here we present a design algorithm for artificial mirtrons and demonstrate, for the first
time, efficient gene knockdown of myotonic dystrophy protein kinase (DMPK) target sequences in Renilla luciferase 39 UTR and
subsequently pathogenic DMPK mRNA, causative of Type I myotonic dystrophy, using artificial mirtrons cloned as eGFP
introns. Deep sequencing of artificial mirtrons suggests that functional mature transcripts corresponding to the designed
sequence were produced in high abundance. They were further shown to be splicing-dependent, Drosha-independent, and
partially dependent on exportin-5, resulting in the precise generation of pre-miRNAs. In a murine myoblast line containing
a pathogenic copy of human DMPK with more than 500 CUG repeats, the DMPK artificial mirtron corrected DM1-associated
splicing abnormalities of the Serca-1 mRNA, demonstrating the therapeutic potential of mirtron-mediated RNAi. Thus, further
development and exploitation of the unique properties of mirtrons will benefit future research and therapeutic RNAi applications
as an alternative to conventional RNAi strategies.
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INTRODUCTION
RNA interference (RNAi) is the cellular process by which
short double-stranded RNAs (dsRNAs) mediate translational
repression and mRNA degradation in a sequence-specific
manner. This pathway has been exploited for therapeutic
application with exogenous mimics such as small interfer-
ing RNAs (siRNAs) (Elbashir et al. 2001), short-hairpin
RNAs (shRNAs) (McManus et al. 2002; Yu et al. 2002), and
artificial micro-(ami)RNAs (Zeng et al. 2002). Each ap-
proach presents limitations that restrict widespread appli-
cation, hence novel technologies should be explored (Sibley
et al. 2010). Mirtrons, first characterized in flies and nema-
todes (Okamura et al. 2007; Ruby et al. 2007) and subse-
quently found in mammals (Berezikov et al. 2007), are
natural pre-miRNA intronic hairpins produced through
splicing of coding mRNAs, unlike intronic pre-miRNAs,
which are produced by Drosha cleavage (Morlando et al.
2008) and have characteristic 39 overhangs (Fig. 1A). We
have previously shown that putative human and murine
mirtrons ectopically expressed in HEK and neuronal cells
can induce functional knockdown of fully and partially
complementary targets (Sibley et al. 2012). This begs the
question of whether artificial mirtrons can be used for re-
search or therapeutic RNAi and if they offer any unique
differences from current RNAi strategies.
Because mirtrons are introns within coding genes, multiple
RNAi effectors can be codelivered with a transgene for
gene therapy under tissue-specific Pol II promoter control.
Exportin-5 can also be oversaturated by shRNAs, negatively
affecting endogenous miRNA function (Boudreau et al.
2009; Pan et al. 2011), and even cause severe toxicity in
mice (Grimm et al. 2006). Mammalian mirtrons, unlike
invertebrate mirtrons or Drosha-processed miRNAs, gen-
erally have blunt ends with mismatched last nucleotides
(Berezikov et al. 2007) and hence are not predicted to be
strong exportin-5 substrates, which have 39 overhangs
(Gwizdek et al. 2003; Okada et al. 2009). Indeed, we have
previously shown that miR-877 and miR-1224 have vari-
able dependence on exportin-5 (Sibley et al. 2012). An
exportin-5-independent pathway for nuclear export may
be able to bypass these molecular bottlenecks. In addition,
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splicing, being tightly defined by regulatory sequences, yields
consistent nucleotides at the ends of the hairpin structures
in contrast to Drosha processing in canonical miRNA bio-
genesis, which can produce heterogeneous ends (Wu et al.
2009), which may lead to off-target effects. These unique
differences may present certain advantages over conven-
tional RNAi effectors in specific applications.
Type I myotonic dystrophy (DM1) is a disease caused by
an autosomal-dominant unstable CUG expansion in the 39
untranslated (39 UTR) region of the myotonic dystrophy
protein kinase (DMPK) gene (Mahadevan et al. 1992). Two
main mechanisms contribute to disease pathogenesis. The
CUG expansion results in nuclear retention of DMPK mRNA
and reduced DMPK protein production (Davis et al. 1997),
which is essential because DMPK knockout mouse models
develop myopathy and cardiac abnormalities (Berul et al.
1996; Jansen et al. 1996; Reddy et al. 1996). The other is
sequestration of splice modulators, such as MBNL1, by the
CUG hairpin, which results in abnormal splicing of multiple
transcripts (Mankodi et al. 2002; Lin et al. 2006). Hence,
knockdown of the mutant DMPK gene without abrogating
functional DMPK protein is desirable. Discriminating CUG
repeat lengths with RNAi for allele-specific silencing is
nontrivial, although CAG repeat antisense oligonucleotides
appear promising as a therapy (Mulders et al. 2009; Wheeler
et al. 2009). Due to the difficulties in discriminating dif-
ferent length CUG expansions in a gene-specific manner,
we reasoned that DMPK presents an attractive target for
mirtron-mediated RNAi, particularly in light of developing
such a gene knockdown and replacement therapy for DM1.
Artificial mirtron design requires consideration of both
splicing and RNAi requirements. In this study, we report the
development of an algorithm that selects for potential mirtron
targets fulfilling these requirements within transcripts of
interest. We show that mirtrons designed against human
DMPK sequences demonstrate the first reported efficacious
RNAi with artificial mirtrons. Further evaluation performed
on a subset of mirtrons and compared against their corre-
sponding shRNAs suggests that the efficacy of an antisense
designed in two different RNAi systems can differ, un-
derpinning the need for further characterization of the
structural determinants of mirtron efficiency. RNA-level
knockdown of full-length DMPK constructs was also dem-
onstrated for two mirtrons. This gene knockdown is de-
pendent on splicing, independent of Drosha and partially
dependent on exportin-5 transport. Lastly, knockdown of
human DMPK in DM500 cells, a model of DM1, corrected
splicing abnormalities in Serca-1 mRNA associated with
CUG sequestration. This study is the first to report the use
of artificial mirtrons for RNAi and demonstrates that this
novel technology has the potential to be exploited for re-
search and therapeutic applications.
RESULTS AND DISCUSSION
Development of an artificial mirtron design algorithm
Toward designing artificial mirtrons capable of silencing
gene targets, we initially incorporated effective shRNA guide
strands into the 39 arm of miR-1226. However, this pre-
dictably did not result in efficient splicing or gene knock-
down due to the absence of essential splicing regulatory
sequences (data not shown). It was therefore clear that both
splicing and RNAi considerations needed to be taken into
account when designing mirtron-based vectors. Thus, an
algorithm for the selection and scoring of artificial mirtron
targets within a gene of interest was developed based on
essential splicing requirements, namely, the consensus 59
splice site (59ss) sequence and the pyrimidine-rich tract
in the 39 arm, and scored according to previously well-
established siRNA design rules (Reynolds et al. 2004) and
additional features that can improve splicing efficiency such
as an unbroken purine tract that will base-pair with the
polypyrimidine tract (Table 1). The scoring system varied
according to the hairpin arm (59 or 39) location of the
antisense/guide stand because of the difference in the number
of purines and pyrimidines required. Artificial mirtrons using
the loop of mmu-miR-1224 were then designed against
human DMPK and introduced as introns within eGFP
(pEGFP-Mirt) downstream from a CMV promoter (Fig. 1B).
Mismatches were introduced to maximize the number of
pyrimidines in the 39 arm and to bias strand selection by
the RISC complex (Khvorova et al. 2003). The target se-
quences and their corresponding artificial mirtrons are
shown in Supplemental Figure S1. In general, the strict re-
quirements for a polypyrimidine tract limits the potential
target sequences of a 39 arm-based mirtron, while the ability
to introduce mismatches into the hairpin allows a looser
definition of the 59 arm-based mirtron.
FIGURE 1. Mirtron biogenesis pathway. (A) Intronic miRNAs are
generated with a Drosha-dependent cleavage, while mirtrons are
generated by splicing. Because splicing, unlike Drosha cleavage, does
not produce defined 39 overhangs, mirtron export may be mediated
by non-exportin-5 pathways. (B) peGFP-Mirt was constructed by
inserting cloning sites into a putative exon splice junction in eGFP for
the introduction of mirtrons.
Artificial mirtron-mediated gene knockdown
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Artificial mirtrons targeted against DMPK mRNA
sequences are capable of target knockdown
In pEGFP-Mirt, the production of an in-frame transcript is
dependent on successful splicing, thus eGFP fluorescence
correlates with splicing efficiency. A psiCheck2.2 vector,
expressing both firefly and Renilla luciferases, was used as a
target vector with one luciferase acting as an internal nor-
malization control for the knockdown of the other in HEK
cells. Target sequences were cloned in tandem in the 39
UTR of Renilla luciferase in dual luciferase constructs, with
four perfectly matched targets per construct. Out of 12
artificial mirtron constructs, seven demonstrated appre-
ciable splicing in HEK cells, with two approaching levels
of efficiency close to that exhibited by a control human
NADH-Coenzyme Q reductase intron 6 (91 nt; NAD) (Fig.
2A,B; Supplemental Fig. S2; Sibley et al. 2012). Luciferase
reporter knockdown by the DMPK targeting mirtrons is
shown in Figure 2C normalized to the ratio when the NAD
intron was used, with eight mirtrons demonstrating signif-
icant gene knockdown and four reducing expression >50%
of NAD levels. The two mirtrons capable of the greatest
reduction in luciferase levels, DMPK-Mirt 5 and DMPK-
Mirt 13, were then selected and compared against a U6
promoter-driven shRNA with the same guide strand se-
quence (Fig. 2D–F). Encouragingly, these demonstrated
comparable levels of knockdown to the shRNA at equimo-
lar ratios. Interestingly, greater gene knockdown was achieved
with DMPK-Mirt 5 than with its corresponding shRNA,
while the opposite was true for DMPK-Mirt 13, similar to
how shRNA knockdown efficacy does not necessarily trans-
late to siRNA knockdown efficacy and vice versa (Siolas
et al. 2005). Further bioinformatic evaluation of natural
mirtron sequences may shed light on the optimal properties
for effective artificial mirtron design. This also suggests that
if short sequences need to be specifically targeted against,
it may be advantageous to examine multiple knockdown
modalities.
To examine if the processed sequences and strand pref-
erence matched mirtron design, high-throughput sequenc-
ing was performed on z18- to 25-nt RNA from HEK cells
transfected with equimolar amounts of DMPK-Mirt 5, 6, 8,
9, 10, and 13. Sequences matched to the mirtrons were then
processed, and a histogram of the number of reads con-
taining the specific nucleotides in the mirtron sequence
plotted after predicted 39 tail nucleotides common to miRNAs
(Newman et al. 2011) were excluded (Fig. 2G; Supplemental
Fig. S3). Agreement between predicted and observed mature
TABLE 1. Design rules for selection of artificial mirtron target sequences
Qualifying criteria (pre-selection)
59 arm Ends with Pyr Pyr Pyr A C (to match the 59ss G T Pur Pur Pur)
At least 13 pyrimidines in the sequence (to match the polypyrimidine tract)
39 arm Six uninterrupted purines (to match the polypyrimidine tract) AND
Purine-rich stretch of at least 10 nt in length with at most one
pyrimidine interruption OR
Purine-rich stretch of at least 13 nt in length with at most two
pyrimidine interruptions OR
Purine-rich stretch of at least 16 nt in length with at most three
pyrimidine interruptions
Criteria in common for both algorithms (Reynolds et al. 2004) Points
T at position 21 +1
A at position 21 +2
A at position 5 +1
Three or more A’s or T’s in the last 5 nt +1
Not G at position 15 +1
A at position 8 +1
Criteria for 59 arm Points
At least 15 pyrimidines in the sequence +1
At least 18 pyrimidines in the sequence +1
Criteria for 39 arm Points
No adjacent U/C in tract, that is, GAGAGA +2
One adjacent U/C in tract, that is, GAGTAG
but not GAGTCA
+1
The qualifying criteria checks for sequences presumed to be essential for splicing, namely, the 59 splice site and the polypyrimidine tract. The
sequences that fit are then subjected to a point-based system based on siRNA design algorithm by Reynolds et al. (2004) and sequences
presumed to improve splicing.
Seow et al.
1330 RNA, Vol. 18, No. 7
 Cold Spring Harbor Laboratory Press on September 3, 2019 - Published by rnajournal.cshlp.orgDownloaded from 
FIGURE 2. Effective knockdown with an artificial mirtron targeted against DMPK. HEK cells were transfected with 250 ng of psiCheck2.2 targets
and 500 ng of mirtron and assayed 2 d later. (A,B) Fluorescence images and quantification of different DMPK mirtrons in a pEGFP-Mirt vector.
(C) Knockdown of the luciferase target by DMPK mirtrons. (D) Sequence of DMPK-Mirt 5 and 13 and their corresponding shRNAs. (E,F)
Luciferase target knockdown by DMPK-Mirt 5, DMPK5 shRNA after transfection with 250 ng of psiCheck2.2 and increasing amounts of mirtron/
shRNA plasmid using the NAD/nonspecific shRNA plasmid to maintain total amount of plasmid transfected (500 ng in total). (G) Deep
sequencing was performed with 18- to 25-nt RNA from HEK cells transfected with DMPK-Mirt 5 and 13. Sequences that were aligned to mirtron
sequences were collected, 39 tails were removed, and the sequences were aligned to chart the frequency of individual nucleotides appearing in the
small RNA species harvested from the cells. (Red nucleotides) Active guide strand; (green nucleotides) flanking exonic sequences. (H) HEK cells
were transfected with 500 ng of phDMPK and 500 ng of mirtron or NAD, and qPCR against hDMPK normalized to 18S RNA was performed on
RNA harvested 2 d after. (*) p < 0.05; (**) p < 0.01; (***) p < 0.001 versus NAD/NS shRNA control.
Artificial mirtron-mediated gene knockdown
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mirtrons validates the design methodology. It is also en-
couraging that strand bias can be very effectively imparted
with mismatches on the distal end of the stem–loop. In-
terestingly, gene knockdown does not correspond to guide
strand abundance, which is not surprising given the var-
iable efficacy of siRNA targeting different sequences on
the same mRNA; more importantly, the abundance of
guide strand does not correspond to eGFP fluorescence,
which hints at additional levels of regulation between
splicing and the production of mature miRNAs by Dicer.
Taken together, this result is the first proof-of-concept dem-
onstration of targeted artificial mirtron-mediated knock-
down. In comparison, equivalent DMPK shRNAs designed
using well-established principles using the mirtron guide
strands result in much higher relative counts of mature
short RNAs (Supplemental Fig. S4), as is expected from the
much stronger U6 promoter and lack of necessity for pro-
cessing at the base of the stem–loop. The bias for the 39 arm
of the shRNA in DMPK sh5a was also unexpected but may
explain why DMPK Mirt 5 knockdown was stronger than
DMPK sh5a.
Following the effective knockdown of luciferase targets,
we investigated if artificial mirtrons were capable of knock-
ing down full-length transcripts. Specifically, DMPK-Mirt 5
and DMPK-Mirt 13 were tested for their RNA knockdown
effect on ectopic DMPK expression in HEK cells. Impor-
tantly, both mirtrons resulted in significant reduction of
DMPK mRNA in HEK cells compared with NAD, as mea-
sured with qPCR (Fig. 2H). This result suggests the pos-
sibility of using these artificial mirtrons against DMPK as
a therapeutic strategy for myotonic dystrophy. However,
before investigating this further, we sought to define the
mirtron origins of these constructs in more detail.
DMPK-Mirt 5 knockdown is dependent on splicing
and exportin-5 but not Drosha
To demonstrate that the artificial mirtron activity is de-
pendent on splicing, we mutated the terminal guanosine
nucleotide in the 59ss to an adenosine, which should affect
splicing but not silencing efficacy (Fig. 2D). As expected,
this abrogated eGFP splicing, as measured by intron-
spanning PCR (Fig. 3A) and eGFP fluorescence (Fig. 3B),
and inhibited target knockdown (Fig. 3C), demonstrating
the dependence on splicing for knockdown. Indeed, this
agrees with the deep-sequencing data (Fig. 2G) which also
clearly show that the mature guide strand, if within the 59
arm, has a clearly defined 59 start site with a near homo-
geneous 39 end. Alternatively, if the mature guide strand is
within the 39 arm (DMPK-Mirt 13 only), then there are
also clearly defined 59 and 39 ends. The uniformity in the 59
and 39 ends of the mature strand is probably due to the
specificity imparted by pre-mRNA splicing. Because Dicer
recognizes its cleavage site with a ‘‘molecular ruler’’ mech-
anism (MacRae et al. 2007), a well-defined pre-miRNA will
likely lead to better Dicer specificity. The homogeneity of
the mature guide strand may be particularly advantageous
in reducing off-target effects that may arise from imprecise
processing of the 59 end by Drosha using other RNAi strat-
egies (Wu et al. 2009).
Next, a lentivirus containing a doxycycline-inducible
Drosha shRNA (Aagaard et al. 2007) or a nonspecific shRNA
was used to stably transfect HEK cell lines. Dependence
on Drosha would result in weaker gene knockdown after
Drosha knockdown. However, knockdown by DMPK-Mirt
5 was independent of Drosha knockdown, while a control
Drosha-dependent amiRNA against a HIV-1 target based on
miR-122 demonstrated decreased knockdown in Drosha-
knockdown cell lines (Fig. 3D).
Because pre-mRNA splicing is an efficient and precise
process, the probable rate-limiting step in mirtron biogen-
esis is debranching of intron lariats, mediated by debranch-
ing enzyme 1 (DBR1) in humans. However, the kinetics of
DBR1 activity are not well known. In the test tube, yeast
DBR1 is highly active, taking <1 min to remove all
branched lariat derived from the CYH2 mRNA from
DBR1-null yeast (Khalid et al. 2005), but expression of a
single murine DBR1 cDNA is not sufficient to fully recover
the lariat accumulation phenotype of Schizosaccharomyces
pombe (Kim et al. 2001), suggesting that the kinetics of
mammalian DBR1 are much slower. Another factor that
limits debranching is the intrinsic stability of the branched
lariat. Certain introns can accumulate as lariats within the
nucleus despite functional DBR1 (Qian et al. 1992). A study
of Pem homeobox gene introns in HeLa cells suggests that
intron half-lives are z9–29 min, the shortest being only
9.4 min, and thus intron degradation is rate-limited by the
lariat debranching step rather than exonuclease activity
(Clement et al. 2001). In support, knockout of yeast DBR1
results in the accumulation of circular lariats lacking their
39 ends, a result of exonuclease activity (Chapman and Boeke
1991). If DBR1 is a slow enzyme compared with nuclear
exonucleases or if artificial mirtrons are unusually stable as
lariats, partial digestion of the 39 end of the lariat could
prevent functional hairpin formation or, alternatively, re-
sult in variable hairpin formation, which could underlie the
difference in mirtron and shRNA efficiency. In support, a
recent study has shown that miR-1017, a 39-tailed mirtron
in Drosophila melanogaster, is processed by 39 exonuclease
to form the pre-miRNA (Flynt et al. 2010). Sequencing re-
sults of artificial mirtrons may have missed these trun-
cated 39 sequences because RNA was sized pre-selection,
thus further work needs to be undertaken to elucidate
the debranching step in mirtron biogenesis and the
rules governing the intrinsic stability of introns. This
may greatly improve the prediction of optimal mirtron
sequences.
Lastly, canonical pre-miRNAs have a characteristic 2-nt
overhang on the 39 arm of the hairpin due to the Drosha
cleavage (Lee et al. 2003). This overhang results in the hairpin
Seow et al.
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being the optimal substrate for exportin-5 (Gwizdek et al.
2003; Okada et al. 2009). The general lack of 39 overhangs in
mammalian mirtrons suggests that they may be exportin-5-
independent. To investigate if mirtron-mediated knock-
down was exportin-5-dependent, we used the pAdvantage
plasmid, which expresses VA-1 RNA, an exportin-5 sub-
strate that competes with miRNAs (Lu and Cullen 2004) and
overexpression of human exportin-5. Target luciferase
constructs were cotransfected with DMPK-Mirt 5 or 13
(Mirt) with pAdvantage (Adv) and/or exporitn-5 (XPO5)
(Fig. 3E). The results showed that DMPK-Mirt 5 and 13
knockdowns were adversely affected by VA-1 competi-
tion. Since VA1 may also have inhibitory effects on Dicer
(Lu and Cullen 2004), we performed rescue assays in the pres-
ence of exogenous exportin-5 to see the contribution of this
protein to the inhibition seen. These showed that the
silencing by DMPK-Mirt 5 and DMPK-Mirt 13 in the pres-
ence of VA1 could be improved by the addition of exog-
enous exportin-5, demonstrating that these mirtrons can
use this nuclear export pathway. Furthermore, the combi-
nation of exportin-5 and pAdvantage resulted in greater
knockdown than with exportin-5 only. This is probably
because VA-1 RNA can dramatically improve translation of
numerous mRNAs including XPO-5 and, in so doing, im-
prove the efficacy of nuclear export of mirtron. In contrast
to previous data with miR-877 (Sibley et al. 2012), a natural
mirtron that is completely inhibited by high levels of VA-1
RNA, VA-1 saturation appears to have less pronounced
effects on DMPK-Mirt 5– and 13–mediated gene knock-
down, suggesting that mirtrons may not exclusively use
exportin-5 as the sole nuclear export mechanism. An in-
triguing nuclear export scenario is that not all mirtronic
pre-miRNA hairpins are debranched within the nucleus,
and some are exported out of the nucleus as branched
lariats. Although the major spliceosome used for artificial
mirtron biogenesis is exclusively nuclear (Rogers and Wall
1980), bioinformatic prediction of the human DBR1 pro-
tein sequence predicts a cytoplasmic localization (Pierleoni
et al. 2006), while lariat debranching activity has also been
detected in both cytosolic and nuclear fractions (Arenas
and Hurwitz 1987). All spliced introns of the Pem homeo-
box gene were found to be present in the cytosolic fraction
FIGURE 3. Dependence on Drosha and Exportin-5 for mirtron-mediated knockdown. (A,B) HEK cells were transfected with 250 ng of
psiCheck2.2 and 500 ng of mirtron/variant and assayed 2 d later. Splicing efficiency of NAD, DMPK-Mirt5, and DMPK-Mirt5US using RT-PCR
with eGFP primers flanking the intron (A) or GFP fluorescence (B). (C) Knockdown of luciferases target by NAD, DMPK-Mirt5, DMPK-
Mirt5US, an unspliceable construct. (**) p < 0.01 versus NAD. (D) Knockdown of putative targets in Renilla luciferases 39 UTR by an shRNA
targeting a HIV transcript (positive control) or by DMPK-Mirt5 in HEK cells stably transfected with Lentivirus (MOI = 1) carrying either
a nonspecific (+Drosha) or Drosha shRNA (Drosha), induced for 8 d with 5 mg/mL doxycycline and transfected on Day 6 with mirtron/
amiRNA and targets. (**) p < 0.01 between +Drosha versus Drosha. (E) HEK cells were cotransfected with 250 ng of target with or without 500
ng of mirtron (Mirt), 500 ng of pAdvantage (Adv), and 500 ng of exportin-5 (XPO5). pEGFP-NAD was used to maintain the total plasmid levels
(1750 ng per well). Cells were harvested 2 d after and assayed for luciferase activity. (*) p < 0.05; (**) p < 0.01; (***) p < 0.001 versus control.
Artificial mirtron-mediated gene knockdown
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of HeLa cells (Clement et al. 2001). These suggest an export
mechanism for branched introns into the cytoplasm from
the nucleus. If so, then the export of the branched lariat will
probably be independent of exportin-5, and, as a result,
mirtron hairpins may be generated in the cytoplasm in
addition to being exported out of the nucleus by exportin-5.
DMPK knockdown by DMPK-Mirt 5 corrects splicing
abnormalities in DM500 cells
Concurrent knockdown of pathogenic alleles and replace-
ment with RNAi-resistant codon-replaced wild-type genes
is a promising therapeutic intervention for diseases caused
by dominant mutations of essential genes. The concept has
been demonstrated with eGFP, autosomal-dominant reti-
nitis pigmentosa, and HIV using shRNAs (Cashman et al.
2005; Unwalla et al. 2006) and siRNAs (Kim and Rossi 2003;
Kiang et al. 2005; O’Reilly et al. 2007). As an alternative to
shRNAs, siRNAs, and artificial miRNAs, mirtrons coex-
pressed within the replacement gene could be driven by the
endogenous RNA polymerase II promoter, offering precise
spatiotemporal control of knockdown while minimizing
the size of the gene cassette such as in the case of DM1. To
evaluate the functional applicability of the DMPK mirtrons,
we decided to investigate phenotypic effects in a cellular
model of DM1.
DM500 cells are murine myoblasts that contain a path-
ogenic copy of human DMPK with more than 500 CUG
repeats (Mulders et al. 2009). Because splicing defects as-
sociated with sequestration of MBNL1, including exon 22
exclusion from the Serca-1 mRNA (Lin et al. 2006), are
found in differentiated DM500 cells, they provide a robust
model for assessing therapeutic correction. DM500 myo-
blasts were transfected with 1 mg of NAD intron, DMPK-
Mirt 5, or DMPK-Mirt 5US in triplicates and differenti-
ated 2 d after transfection. After 7 d of differentiation, the
myotubes were imaged and the RNA was harvested. GFP
expression was relatively low (Fig. 4A), although signifi-
cantly greater fluorescence and hence more active mirtron
effectors were noted earlier post-transfection. Quantitative
PCR analysis of human DMPK mRNA normalized to
murine GAPDH shows a significant reduction in patho-
genic DMPK (Fig. 4B), suggesting that DMPK-Mirt 5 is
capable of knocking down the toxic pathogenic DMPK
RNA. Furthermore, RT-PCR of Serca-1 mRNA demon-
strated increased inclusion of exon 22 in DM500 cells,
suggesting that MBNL-1 sequestration is partially re-
versed by knockdown of mutant human DMPK mRNA
(Fig. 4C). This inclusion of Serca-1 exon 22 after mirtron-
mediated pathogenic DMPK knockdown in DM500 cells
implies that MBNL-1 has been released from CUG seques-
tration to mediate normal splicing and provides evidence
that mirtron-mediated gene knockdown can be used as DM1
gene therapy.
CONCLUSION
In this study, we investigated if the endogenous mirtron
pathway is exploitable for gene knockdown. A selection
algorithm for potential artificial mirtron target sequences
was designed, and artificial mirtrons capable of effective
RNAi were generated in an eGFP cassette. Selected se-
quences demonstrated efficacy against native and recombinant
target RNA sequences. DMPK-Mirt 5–mediated knockdown
was found to be independent of Drosha processing but de-
pendent on splicing and exportin-5, consistent with the
biogenesis mechanism of natural mirtrons (Ruby et al. 2007),
although exportin-5 may not be the sole nuclear export
system used by mirtrons. In terms of therapeutic applica-
tion, Serca-1 splicing defects were corrected in a cellular
model of myotonic dystrophy with DMPK-Mirt 5, suggest-
ing that a therapeutic level of nuclear RNAi was achieved.
FIGURE 4. Functional effects of mirtron-mediated DMPK knock-
down in DM500 cells. DM500 cells were transfected with 1 mg of
NAD, DMPK Mirt 5, or DMPK Mirt 5US and differentiated 2 d after
transfection. After 7 d in differentiation medium, RNA was harvested.
(A) Representative GFP fluorescence and merged brightfield and
eGFP images of differentiated DM500 before harvest. (B) qPCR of
DMPK cDNA normalized to mGAPDH cDNA. (C) Representative
RT-PCRs of Serca-1 using primers flanking exon 22. Sequestration
of MBNL1 leads to exclusion of exon 22. The graph below shows the
relative ratio of cDNA with exon 22 to cDNA without exon 22. (*)
p < 0.05 versus NAD control.
Seow et al.
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This suggests that DMPK-Mirt 5 can potentially be used
in a gene knockdown and replacement strategy for thera-
peutic correction of DM1. It will be interesting to see if this
construct can successfully be incorporated into a DM1 gene
knockdown and replacement therapy by using a construct
incorporating multiple DMPK-targeting artificial mirtrons
as separate introns within an RNAi-resistant host DMPK
transcript in combination with the endogenous DMPK pro-
moter (Storbeck et al. 1998). This is the first demonstration
that artificial mirtrons can be exploited for gene knock-
down, and this work will now lead to further development
of this novel therapeutic tool, in particular for combinato-
rial gene therapy applications.
MATERIALS AND METHODS
Unless otherwise stated, all chemicals were obtained from Sigma-
Aldrich, and all enzymes used were obtained from New England
Biolabs.
Plasmids
pEGFP-Mirt and cloning of mirtrons were previously described
(Sibley et al. 2012). Briefly, a BbsI-excised sequence was placed
between two fragments of eGFP, and introns were introduced in
that site with annealed oligonucleotides (Fig. 1B). Luciferase tar-
gets were produced by annealing and ligating the relevant targets
(Supplemental Table S1) as oligonucleotides into psiCheck2.2
(kind gift from Dr. Marc Weinberg) (Supplemental Fig. S5)
downstream from Renilla luciferase between XhoI and NotI sites
as previously described by others (Ely et al. 2008). The luciferase
targets for DMPK-Mirt1, 4, 5, and 6 were cloned as a concatemer
of target sequences, as were targets for DMPK-Mirt 7–10 and
DMPK-Mirt 11–14 (Supplemental Table S1).
The relevant shRNAs used for comparison were produced by
PCR of the U6 promoter with the reverse complement of the
shRNA followed by a reverse U6 primer. The PCR product was
then TA-cloned into pCR2.1 (Invitrogen). The final plasmid size
is similar to pEGFP-Mirt clones.
Human DMPK amplified from a human DMPK cDNA plasmid
(Invitrogen) was cloned into pEGFP-C1 after removing EGFP with
NheI and HindIII to produce phDMPK. Human exportin-5 was
PCRed from human HEK random nonamer-primed cDNA and
cloned into pEGFP-C1 downstream from eGFP using the BspEI and
XhoI restriction sites. pAdVantage was obtained from Promega.
Cell culture and transfection
HEK cells were cultured in DMEM Glutamax supplemented with
10% FBS and antibiotics and incubated at 37°C in 5% CO2.
DM500 cells (gift from Dr. Wansink) were maintained in pro-
liferation medium (DMEM, 20% FCS, 20 U/mL g-interferon, 1%
antibiotics) in plates coated for 30 min with 0.2% gelatin at 33°C
in 10% CO2. For differentiation of DM500 cells, plates were coated
with 500 mL of a 1/100 dilution of BD Matrigel (BD #356234), and
cells were grown in proliferation medium until confluent, then
differentiated with differentiation medium (DMEM, 5% horse
serum, 1% antibiotics). Transfection of HEK cells was performed
using Lipofectamine 2000 (Invitrogen) in HEK cells and JetPEI
(Polyplus Transfections) in DM500 cells as per the manufacturer’s
instructions in 24-well plates. When the experiment required a
control NAD plasmid or shRNA, an amount corresponding to the
mirtron plasmid was used. The cells were imaged and lysed 48 h
post-transfection.
RT-qPCR and PCR
Reverse transcription was performed with 1 mg of RNA and
random nonamers using Expand Reverse Transcriptase (Roche) as
per the manufacturer’s instructions. qPCR experiments were per-
formed on an ABI7000 thermal cycler in 20-mL reactions, with 30
nM primer and 0.2 mL of each cDNA preparation, using Precision
qPCR Mastermix (Primer Design) as per the manufacturer’s
instructions. Intron-spanning PCR was performed with BioTaq
(Bioline) using primers flanking the intron. The primers used for
qPCR and PCR are listed in Supplemental Table S1.
High-throughput sequencing
HEK cells were grown in 24-well plates to 80% confluence and
transfected with 500 ng of each mirtron or shRNA construction
per well. Small RNA libraries were prepared with the Small RNA
v1.5 Sample Prep Kit following the manufacturer’s instructions
(Illumina). Briefly, total RNA was isolated from each transfection
by TRIzol extraction and pooled. The RNA was ligated with
a 39-RNA adaptor modified to target small RNAs with 39-hydroxyl
groups, and then with a 59-RNA adaptor. Reverse transcription
followed by PCR was performed to select for adaptor-ligated
fragments, and double-stranded DNA libraries were size-selected
by PAGE purification (6% TBE PAGE). Libraries were sequenced
on a Genome Analyzer IIx for 36 cycles following the manufac-
turer’s protocols. The image analysis and base calling were done
using Illumina’s GA Pipeline. Adaptors were trimmed with
Biopieces remove_adapter script, and remaining sequences were
aligned against full-length mirtron hairpins.
Fluorescence quantification and Dual-Luciferase
Assay
The luciferase assay was performed with Promega’s Dual-Luciferase
Reporter Assay System as per the manufacturer’s instructions.
Briefly, HEK cells were lysed in 100 mL of passive lysis buffer, and
background-subtracted eGFP fluorescence was measured in a 96-well
format with 20 mL of each sample using Victor3 (PerkinElmer).
Twenty-five microliters of Luciferase Buffer II was added to the
sample and luminescence was measured. Twenty-five microliters
of Stop & Glo Buffer was then added to measure Renilla luciferase
activity. The Renilla luciferase signal was then normalized to the
firefly luciferase signal for all luciferase experiments.
Microscopy
HEK cells transfected with the mirtron (250 ng) only were imaged
48 h post-transfection with a Leica DMIRB microscope (Leica
Microsystems) with a 203 objective to obtain brightfield and GFP
fluorescence.
Statistics
All experiments, unless otherwise stated, were performed in
triplicate. All error bars used in this report are standard deviations.
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Statistical significance was determined by a one-tailed Student’s
t-test assuming equal variance.
SUPPLEMENTAL MATERIAL
Supplemental material is available for this article.
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